Display Settings:

Format

Send to:

Choose Destination
    Breast Cancer Res. 2009;11(4):207. Epub 2009 Jul 15.

    Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer.

    Source

    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Holcombe Boulevard, Houston, TX 77030, USA. pmorrow@mdanderson.org

    Abstract

    Human epidermal growth factor receptor (HER)2 over-expression is associated with a shortened disease-free interval and poor survival. Although the addition of trastuzumab to chemotherapy in the first-line setting has improved response rates, progression-free survival, and overall survival, response rates declined when trastuzumab was used beyond the first-line setting because of multiple mechanisms of resistance. Studies have demonstrated the clinical utility of continuing trastuzumab beyond progression, and further trials to explore this concept are ongoing. New tyrosine kinase inhibitors, monoclonal antibodies, PTEN (phosphatase and tensin homolog) pathway regulators, HER2 antibody-drug conjugates, and inhibitors of heat shock protein-90 are being evaluated to determine whether they may have a role to play in treating trastuzumab-resistant metastatic breast cancer.

    PMID:
    19664181
    [PubMed - indexed for MEDLINE]
    PMCID: PMC2750101
    Free PMC Article

    Images from this publication.See all images (1) Free text

    Figure 1

    Publication Types, MeSH Terms, Substances

    Publication Types

    MeSH Terms

    Substances

      Supplemental Content

      Click here to read Click here to read

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk